Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone

NCT01685268 is registered in ClinicalTrials.gov with Astex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01685268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01685268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Lead sponsor
Astex Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2012
Completion date
December 31, 2014
Enrollment
49 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer